AstraZeneca Trial Failure Sends Shares Lower
AstraZeneca trial failure in Phase 3 CARDIO-TTRansform left eplontersen short of its goal and triggered a roughly 9% share selloff on July 9, 2026.
KEY TAKEAWAYS
- Phase 3 CARDIO-TTRansform found eplontersen did not meet the primary endpoint through Week 140.
- Shares fell about 9%, erasing billions in market value and raising pipeline credibility concerns.
- Companies will present full CARDIO-TTRansform data at the European Society of Cardiology Congress August 2026.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
AstraZeneca PLC said in a July 9, 2026 release that its Phase 3 CARDIO-TTRansform trial of eplontersen (marketed as WAINUA and Wainzua in the EU) failed to meet its primary endpoint through Week 140. The compound did not significantly reduce the composite of cardiovascular mortality and recurrent cardiovascular events compared with placebo, triggering a nearly 9% drop in shares and renewed investor concern about the company’s late-stage pipeline.
CARDIO-TTRansform Trial Results and Subgroup Findings
The trial tested eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), measuring a composite endpoint of cardiovascular death and recurrent clinical events on top of standard care. While the overall study missed this primary efficacy goal, a prespecified monotherapy subgroup showed a nominally significant hazard ratio of 0.71. Patients already receiving stabilizer therapy experienced no treatment benefit. The companies reported that eplontersen was well tolerated, with a safety profile consistent with previous studies.
Market Reaction and Corporate Outlook
Following the trial update, AstraZeneca shares fell about 9%, erasing billions in market value and prompting scrutiny of its late-stage development program. The company did not revise its financial guidance or announce new regulatory steps for the ATTR-CM indication. It reiterated that WAINUA is approved for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN/ATTRv-PN) in more than 20 countries, including the EU under the name Wainzua. The release did not outline a new filing plan or label-expansion strategy for ATTR-CM.
AstraZeneca and partner Ionis said they will continue analyzing the full dataset and plan to present complete results at the European Society of Cardiology Congress in August 2026. Investors and clinicians are expected to focus on the full data for further context on the subgroup signal and safety profile.
"WAINUA® (eplontersen) has now been approved" for hATTR-PN/ATTRv-PN, the companies noted, but the trial "did not meet the primary efficacy endpoint."
